MEG3 and osteosarcoma: The results showed that compared to the MEG3 group, the cRGD-modified exosomes emitted stronger fluorescence signals in the tumor site, confirming that the cRGD-modified exosomes had a stronger ability to target lncRNA delivery to osteosarcoma.